Purpose: To investigate the antinociceptive effect of the essential oil from the aerial parts of Gundelia. tournefortii (EOGT) in various experimental models

Artemisia herba-alba (A. h.-a.) has wide use in traditional medicine for the relief of coughing, healing external wounds, and treatment of pain associated with gastrointestinal disturbances. We investigated in vivo antinociceptive and anti-inflammatory activities of an aqueous extract (aq. ex.) and two isolated compounds obtained from aerial parts of A. h.-a. The analgesic effects of aq. ex. (10, 31.6, 100, 316, and 1000 mg/kg), astragalin, and eupatilin (both, 0.316, 1, 3.16, 10, 31.6, and 100 mg/kg) were studied using the hot-plate test in mice and formalin test in rats. The effects were compared with those of 5 mg/kg morphine. Dosedependent analgesic effects of aq. ex., astragalin, and eupatilin were clearly manifested in both hot-plate assay and early and late phases of formalin-induced paw licking. These effects were significantly but partly reduced by the opioid receptor antagonist naloxone (5 mg/kg). The same range of doses of aq. ex., astragalin, and eupatilin caused dose-dependent suppression of carrageenan-induced paw edema in rats. Thus, we demonstrated that A. h.-a. possesses noticeable antinociceptive and anti-inflammatory activities; our data support the reasons for using this plant as a remedy for treatment of pain and inflammation. Antinociceptive and anti-inflammatory actions of A. h.-a. are considerably related to the presence of astragalin and eupatilin.

No abstract

Background: Isorhamnetin is a flavonoid that is found in medical plants. Several studies showed that isorhamnetin has anti-inflammatory and anti-obesity effects. This study aims to investigate the anti-diabetic effects of isorhamnetin in a high-fat diet and Streptozotocin-(HFD/STZ)-induced mice model of type 2 diabetes. Materials and Methods: Mice were fed with HFD followed by two consecutive low doses of STZ (40 mg/kg). HFD/STZ diabetic mice were treated orally with isorhamnetin (10 mg/kg) or (200 mg/kg) metformin for 10 days before sacrificing the mice and collecting plasma and soleus muscle for further analysis. Results: Isorhamnetin reduced the elevated levels of serum glucose compared to the vehicle control group (p < 0.001). Isorhamnetin abrogated the increase in serum insulin in the treated diabetic group compared to the vehicle control mice (p < 0.001). The homeostasis model assessment of insulin resistance (HOMA-IR) was decreased in diabetic mice treated with isorhamnetin compared to the vehicle controls. Fasting glucose level was significantly lower in diabetic mice treated with isorhamnetin during the intraperitoneal glucose tolerance test (IPGTT) (p < 0.001). The skeletal muscle protein contents of GLUT4 and p-AMPK-α were upregulated following treatment with isorhamnetin (p > 0.01). LDL, triglyceride, and cholesterol were reduced in diabetic mice treated with isorhamnetin compared to vehicle control (p < 0.001). Isorhamnetin reduced MDA, and IL-6 levels (p < 0.001), increased GSH levels (p < 0.001), and reduced GSSG levels (p < 0.05) in diabetic mice compared to vehicle control. Conclusions: Isorhamnetin ameliorates insulin resistance, oxidative stress, and inflammation. Isorhamnetin could represent a promising therapeutic agent to treat T2D.

No abstract